Business & Industry

Bristol Myers Squibb has entered into a strategic agreement with Anthropic to deploy its Claude platform across global operations. This initiative moves beyond standard conversational tools, aiming to embed agentic AI capabilities directly into core workflows, including research, clinical...

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on a proposed Rare Disease Therapies Framework a regulatory proposal that would introduce a new development and authorisation pathway for therapies targeting rare diseases in the...

QIAGEN's Digital Insights bioinformatics division is set to integrate NVIDIA's accelerated computing infrastructure and the BioNeMo platform to strengthen AI-driven drug discovery capabilities for pharmaceutical and biotechnology researchers. The collaboration aims to make AI more actionable in research settings...

The global Decentralized Clinical Trials Market is expected to grow from USD 9.74 billion in 2025 to USD 34.13 billion by 2035, registering a compound annual growth rate (CAGR) of 13.36% during the forecast period from 2026 to 2035....

AstraZeneca's hypertension drug baxdrostat, branded as Baxfendy, has received approval from the U.S. Food and Drug Administration, opening a new treatment pathway for millions of patients whose high blood pressure remains uncontrolled despite existing therapies. The Anglo-Swedish pharmaceutical company...

The European Union has moved closer to implementing new measures aimed at protecting the availability of essential medicines and reducing exposure to external supply risks, as lawmakers advanced the Critical Medicines Act framework first introduced in March 2025. The...

Agilent Technologies and Veeda Lifesciences have announced a strategic collaboration aimed at strengthening regulatory-aligned analytical and bioanalytical workflows for biopharma development as GLP-1 and other advanced therapeutic modalities continue to progress across global pipelines. The partnership will combine Agilent’s...